(3.220.231.235) 您好!臺灣時間:2021/03/08 05:51
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:鄭明俊
研究生(外文):Ming-Chun Cheng
論文名稱:尿毒症患者接受不同血液透析膜治療前與治療後,血漿中MMP-2、MMP-9、TIMP-1及TIMP-2之變化
論文名稱(外文):Plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in uremia patients before and after hemodialysis
指導教授:謝易修謝易修引用關係
指導教授(外文):Yih-Shou Hsieh
學位類別:碩士
校院名稱:中山醫學大學
系所名稱:生物化學研究所
學門:生命科學學門
學類:生物化學學類
論文種類:學術論文
論文出版年:2002
畢業學年度:90
語文別:中文
論文頁數:48
中文關鍵詞:慢性腎絲球腎炎糖尿病性腎病變基質金屬蛋白基質金屬蛋白抑制劑血液透析血液透析治療前血液透析治療後
外文關鍵詞:CGN chronic glomerulonephritisDN diabetic nephropathyMMPs matrix metalloproteinasesTIMPs tissue inhibitor of matrix metalloproteinasesHD hemodialysisPre-HD pre hemodialysisPost-HD post hemodialysis
相關次數:
  • 被引用被引用:5
  • 點閱點閱:234
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:71
  • 收藏至我的研究室書目清單書目收藏:2
許多研究報告指出,血液透析治療過程中體內許多物
質如:β2 -microglobulin、interlukin、TNF-α….會有不同
程度改變以因應生理的變化。在這個研究中:我們收集了
40名長期接受規則性血液透析尿毒症患者分成3組使用不
同透析膜(超過3個月),於透析治療前與治療後利用Zym-
ography和ELISA分析血漿中MMP-2,MMP-9,TIMP-1
和TIMP-2變化。結果發現,經過4個小時血液透析治療
後,血漿中MMP-9和MMP-2下降大約70% 和92% ( p<
0.001和p< 0.05 個別地 )。除此之外,TIMP-2血漿濃度
較透析前增加6-8倍。TIMP-1濃度則沒有明顯變化。進一
步統計發現不同性別、原發病、透析膜會有不同差異。上
述結果第一次顯示出MMPs/TIMPs系統和血液透析治療有
關。其於尿毒症患者體內生理意義則需進一步探討。

Many reports have indicated that among hemodialysis process , m-
any plasma proteins level change for physiological condition , eg : β2-
microglobulin , interlukins and TNF-α….…。In this study , we collect
40 uremia patients undergoing regular hemodialysis above 3 months , di-
vided three different dialysis membrane type , and assay Pre-hemohialy-
sis and Post-hemodialysis MMP-2 , MMP-9 , TIMP-1 and TIMP-2 by
Zymography and ELISA method . We found that after 4 hours hemodial-
ysis process decreased the MMP-9 and MMP-2 levels to 70~92% ( P<0.001 and P<0.05 respectively) , and increased the TIMP-2 levels to 6- to 8-fold of the Pre-hemodialysis level that within the physiological range . TIMP-1 levels were not affected by the hemodialysis process . These results first indicated that hemodialysis treatment associated with MMPs/TIMPs system in uremia patients undergoing regular hemodialy-sis , which physiological purpose needed further discussion .

尿毒症患者接受不同血液透析膜治療前與治療後,血漿中
MMP-2、MMP-9、TIMP-1及TIMP-2之變化-----------------1
中文摘要-----------------------------------------------------------------------2
英文摘要-----------------------------------------------------------------------3
前言-----------------------------------------------------------------------------4
縮寫-----------------------------------------------------------------------------15
動機-----------------------------------------------------------------------------16
實驗材料與方法--------------------------------------------------------------17
檢體來源-----------------------------------------------------------------------22
統計方法-----------------------------------------------------------------------23
結果-----------------------------------------------------------------------------24
討論-----------------------------------------------------------------------------27
圖表-----------------------------------------------------------------------------31
參考文獻-----------------------------------------------------------------------40

1. 賴永勳,黃尚志,楊五常暨中華民國腎臟醫學會透析評估委員:
臺灣地區八十六年度透析評估報告。p177-179 , p188
2. Andrassy K, Bommer ER: Effects of Hemodialysis on platelet.
Contr.Nephrol. 1987; 59: 26-34
3. Hakim RM, Schafer Al: hemodialysis-associated platelet activation
and thrombocytopenia. Am. J. Med. 1985; 78: 575-580
4. Sreeharan N, Crow MJ, Salter MCP et al: membrane effect on plate-
let function during hemodialysis: A comparison of cuprophan and po-
lycarbonate. Artif. Organs. 1982; 324-327
5. Raij L , Kay NE: Effect of Hemodialysis membranes on humen lym-
phocyte natural killer function. Nephrol., vol.59, 17-25
( karger , basel 1987 )
6. Geyo F, Yamada T, Odani S et al: a new form of amyloid associated
with chronic hemodialysis was identified as β2-microglobulin .
Biochem. Biophys. Res. Commun. 1985; 129: 701-706
7. Nelon, A. R., Fingleton, B., Rothenberg, M. L and Matrisian, L.M
Matrix metalloproteinase : biological activity and clinical implication
J. Clin. Oncol. 2000; 18: 1135-1149 8. Woessner, J.F.Jr The matrix metalloproteinase family, in Parks WC,
Mecham RP (eds): Matrix metalloproteinase. San Diego, CA ,
Academic Press, 1998: 1-14
9. Fini, M. E., Cook, J. R., Mohan, R, et al. Regulatio of gene expres-
sion in parks WC, Mwcham, R. P. (eds): Matrix metalloproteases.
San Diego, CA, Academic press 1998: 299-256
10. Kugler, A: Matrix Metalloproteinases and their inhibitors.
Anticancer Res. 1999; 19: 1589-1592
11. Murphy, G., Reynolds, J. J. and hembry, R . M .: Metalloproteinases
and cancer invasion and metastasis. Int. J.Cancer 1992; 44: 757-760
12. Murphy, G. and Docherty, A . J: Matrix metalloproteinases and their
inhibitors. Am. J. Respir. Cell Mel. Biol. 1992; 7: 120-125
13. Gomez, D. E., Alonso, D. F., Yoshiji, H. and Thorgeirsson, U.P:
Tissue inhibitor of metalloproteinases: structure, regulation and bi-
ological functions. Eur. J. Cell Biol. 1997; 74: 111-122
14. Hueboner, K., Isobe, M., Gasson, J.C., Golde, D.W. and Croce ,C.
M : Localization of the gene encoding erythroid-potentiating activ-
ity to chromosome region Xpll. 1- Xpll. 4. Am. J. Hum. Genet. 1986
; 38: 819-826
15. Woessener, J. F. : Matrix metalloproteinases and their inhibitors in
connective tissue remodeling. FASEB J. 1991; 5: 2145-2155
16. Kolkenbrock, H., Hecker, A., Zimmermann, J. and Ulbrich, N.
: Generation and activity of ternary gelatinase B/TIMP-1/LMW-str-
omelysin-1 complex. Biol. Chem. Hoppe. 1995; Seyler 376: 495-500
17. Goldberg, G. I., Strongin, A., Collier, I.E., Genrich, L. T. and Marmer
, B. L.: Interaction of 92-kDa type Ⅳcollagenase with the tissue inh-
ibitor of metalloproteinase prevents dimerziation , complex formation
with interstital collagenase , and activation of the proenzyme with st-
romelysin. J. Biol. Chem. 1992; 267: 4583-4591
18. Johnson, M. D., Kim, H. R., Chesler, L., Tsao, W. G., Bouck, N.
and Polverini, P. J.: Inhibition of angiogenesis by tissue inhibitor of
metalloprotrinase. J. Cell Physiol. 1994; 160: 194-202
19. Takigawa, M., Nishida, Y., Suzuki, F., Kishi, J., Yamashita, K . and
Hayakawa, T.: Induction of angiogenesis in chick yolksac membrane
by polyamines and its inhibition by tissue inhibitor of metalloprotein-
ases ( TIMP-1 and TIMP-2 ). Biochem. Biophys. Res.1990; 171:1264
1271
20. Thorgeirsson, U. P., Yoshiji, H., Sinha C. C. and Gomez, D. E.:
Breast cancer : tumor neovasculature and the effect of tissue inhibi-
tor of metalloproteinase-1 (TIMP-1) on angiogenesis. In Vivo. 1996
; 10: 137-144
21. Alvarez, O. A., Carmichael, D. E. and DeClerck, Y. A. : Inhibition
of collagenolytic activity and metastasis of tumor cells by a recombi-
nant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst
1990; 82: 589-595
22. DeClerck, Y. A., Perez, N., Shimada, H., Boone, T. C., Langley, K. E.
and Taylor, S. M. : Inhibition of invasion and metastasis in cell transf-
ected with an inhibitor of metalloproteinases. Cancer Res. 1992; 52:
701-708
23. Schultz, R. M., Silberman, S., Persky, B., Bajkowski, A. S. and
Carmichael, D. F.: Inhibition of human recombinant tissue inhibitor
of metalloproteinase of human amnion invasion and lung colonization
by murine B16-F10 melanoma cells. Cancer Res. 1988; 48:5539-5545
24. Thorgeirsson, U. P., Liotta, L. A., Kalebic, T., Margulies, I. M.,
Thomas, K., Rios. Candelore, M. and Russo R. G.: Effect of natural
protease inhibitors and a chemoattractant on tumor cell invasion in
vitro. J. Natl. Cancer Inst. 1982; 69: 1049-1054
25. Flenniken, A. M. and Williams, B. R. : Developmental expression of
the endogenousTIMP gene and a TIMP-lacZ fusion gene in transgenic
mice. Genes Dev. 1990; 4: 1094-1106
26. DeClerk, Y. A., Szpirer, C., Aly, M. S., Cassiman, J. J., Eeckhout, Y.
and Rousseau, G.: The gene for tissue inhibitor of metallproteinase-2
is localizied on human chromosome arm 17q25. Genomics 1992; 14:
782-784
27. Boone, T. C., Johnson, M. J., DeClerck, Y. A. and langley, K. E.
: cDNA cloning and expression of a metalloproteinase inhibitor rela-
ted to inhibitor of metalloproteinases. Proc. Natl. Acad. Sci.USA
1990; 87: 2800-2804
28. Shapiro, S. D., Kobayashi, D. K. and Welgus. H. G. : Idetification of
TIMP-2 in human alveolar macrophages. J. Biol. Chem. 1992; 267:
13890-13894
29. Stetler-Stevenson, W. G., Brown, P. D. Onisto, M., Levy, A. T. and
Liotta, L. A.: Tissue inhibitor of metalloproteinase -2(T-IMP-2)
mRNA expression in tumor cell lines and human tumor tissue. J.
J. Biol.Chem. 1990; 265: 13933-13938
30. Apte, S. S., Olaen, B. R. and Murphy, G. : The gene structure of tiss-
ue inhibitor of metalloproteinase (TIMP-3) and its inhibitor activaties
define the distint TIMP gene family. J. Biol. Chem. 1995; 270: 14313
-14318
31. Leco, K. J., Khokha, R., Pavloff, N., Hawkes, S. P. and Edwards, D. R
. : Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an eetracellular
matrix-associated protein with a distinctive pattern of expression in
mouse cells and tissues. J. Biol.Chem. 1994; 269: 9352-9360
32. Stricklin, G. P. and Welgus, H. G. : Human skin fibroblast collagenase
inhibitors: purification and biological characterization. J. Biol. Chem.
1983; 258: 12252-12258
33. Yang, T. T. and Hawkes, S. P.: Role of the 21-kDa protein TIMP-3 in
in oncogenic transformation of cultured chicken embryofibroblast .
Proc. Natl. Acad. Sci. USA 1992; 89: 10676-10680
34. Wick, M., Burger, C., Bnsselbach, S., Lucibello, E. and Muller, R.
: A novel member of human tissue inhibitor of metalloproteinases
(TIMP) gene family is regulated during GI progression, mitogenic
stimulation, diferentiation and senescence. J. Biol. Chem. 1994; 269:
18953-18960
35. Greene, J., Wang, M., Liu, Y. E., Raymond, L. A., Rosen, C. and
Shi, Y. E. : Molecular colning and characterization of human tissue
inhibitor of metalloproteinase 4. J. Biol.Chem. 1996; 271: 30375-
30380
36. Schaefer, R. M., Paczek. L. and Heidland. A.: Cytokine Production
by Monocytes During Haemodialysis. Nephrol. Dial. Transplant.
1991; suppl 2: 14-17
37. Betz M, Haensch GM, Rauterberg EW, Bommer J, Ritz E.: Cupram-
monium membranes stimulate interlukin-1 release and arachidonic
acid metabolism in monocytes in the absence of complement .
Kidney Int. 1988; 34: 67-73
38. Raymond M. Hakin, Douglas T. Fearon, and J. Michael Lazarus.
: Biocompatibility of dialysis membranes: Effect of chronic comple-
ment activation. Kideny Int. 1984; 26: 194-200
39. Trang DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH.: Effect
of vitamin E-bounded membrane on the 8-hydroxy 2'-deoxyguanos-
ine level in leukocyte DNA of hemodialysis patients. Kidney Int.2000
; 58: 790-799
40. Kleinmon KS, Coburn JW: Amyloid syndrome associated with hem-
odialysis. Kindney Int. 1989; 35: 567-575
41. Stone WJ, Hakim RM: Beta-2-microglobulin amyloidosis in long-te-
rm dialysis patients. Kidney Int. 1989; 35: 177-183
42. Floege J, Granolleras C, Koch KM, Shaldon S: Which membrane ?
Should beta-2 microglobulin decide on the choice of today's hemodia-
lysis membrane ? Nephron. 1988; 50: 177-181
43. Raymond M. Hakim, rebecca L. Wingard, Leigh Husni, Robert A.
Parker, and Tom F. ParkerⅢ: The effect of membrane biocompatibi-
lity on plasma β2-microglobulin level s in chronic hemodialysis pat-
ients. J. Am. Soc. Nephrol. 1996; 7: 472-478
44. Ebihara I, Nakamura T, Tomino Y, Shimada N, Koide H: Metallopro-
teinase-9 mRNA expression in monocytes from patients with chronic
renal failure. Am. J. Nephrol. 1998; 18: 305-310
45. Ohashi K, Kawai R, Hara M, Okada Y, Tachibana S, Ogura Y:
Increased matrix metalloproteinases as possible cause of osseoarti-
cular tissue destruction in long-term haemodialysis and beta 2-micr-
oglobulin amyloidosis. Virchows Arch. 1996; 428: 37-46
46. Gutierrez A, Alvestrand A, Wahren J, Bergstrom J: Effect of in vivo
contact between blood and dialysis membranes on protein catabolism
in humans. Kidney Int. 1990; 38: 487-494
47. Tayeb JS, Provenzano R, El-Ghoroury M, Bellovich K, Khairullah Q,
Pieper D, Morrison L. Calleja Y: Effect of biocompatibility of hemo-
dialysis membranes on serum albumin levels. Am. J. Kidney Disease.
2000; 35: 606-610
48. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, Sheih SD
: Cytokine production during hemodialysis : effects of dialytic me-
mbrane and complement activation. Am. J. Nephrol. 1996; 16: 293-
299
49. Himmelfarb J, Hakim RM: The use of biocompatible dialysis mem-
branes in acute renal failure.Adv Ren Replace Ther. 1997; 4: 72-80
50. Buoncristiani U, Galli F, Rovidati S, Albertini MC, Campus G, Can-
estrari F: Oxidative damage during hemodailysis using a vitamin-E
modified dialysis membrane: a preliminary characterization. Nephrol.
1997; 77: 57-61
51. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam
DW, Stephenson TJ, Rees RC: Cytokine and chemokine regulation of
pro-MMP-9 and TIMP-1 production by human peripheral blood lyph-
ocytes. J. Immunol. 1997; 158: 2327-2333
52. Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immu-
nity. J Immunol. 1996; 159-6 : 1-4
53. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M
Nitric oxide mediates interlukin-1-induced gene expression of metal-
loproteinases and basic fibroblast growth factor in cultured rabbit arti-
cular chondrocytes. J. Biochem. (Tokyo). 1998; 123; 431-439
54. Rajagopalan S, Meng XP, Ramasmy S, Harrison DG, Galis ZS:
Reactive oxygen species produced by macrophage-dervied foam ce-
lls regulate the activity of vascular matrix metalloproteinases in vitro.
J. Clin. Invest. 1996; 98; 2572-2579
55. Hi YE, Liu Y: Stromal-epithelial interaction in type Ⅵ collagenase
expression and activation: The role in cancer metastasis. In: Goldberg
ID, Rasan EM (eds): Epithelial-Mesenchymal Interations in Cancer.
Switzerland, Birkhausar Berlag Basel, 1995, pp215-234
56. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Romanini C, Biag-
ini G: Increased serum 72 Kda metalloproteinase in serous ovarian
tumors: comparsion with CA125. Anticancer Res. 1996; 16: 2123-
2127
57. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y,
Saisho H: Elevated plasma levels of matrix metalloproteinase-9 (92-
-kd typeⅥ collagenase/gelatinase B) in hepatocellular carcinoma.
Hepatology 1996; 24: 1058-1062
58. Moore DH, Allison B, Look KY, Sutton GP, Bigsby RM: Collagenase
expression in orvarian cancer cell line. Gynecol. Oncol. 1997;65: 78-
82
59. Endo K, Maehara Y, Baba H, Yamamoto M, Tomissaki S, Watanabe
A, Kakeji Y. Sugimachi K: Elevated levels of serum plasma metallo-
proteinases in patients with gastric cancer. Anticancer Res. 1997; 17
: 2253-2258
60. Celentano DC, Frishman WH: Matrix metalloproteinases and cornoa-
ry artery disease: a novel therapeutic target. J. Clin. Pharmacol. 1997;
37: 991-1000
61. Ohashi K: Pathogenesis of beta-2 microglobulin amyloidosis .
Path. Int. 2001; 51: 1-10

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔